Medical school costs an average of $250,000 for a four-year degree at a public institution. At private schools, that number climbs past $330,000. The doctors most likely to work in rural towns, tribal lands, and low-income urban neighborhoods after graduation are, statistically, the ones who took on the most debt to get there — and who relied on federal graduate loan programs to make attendance possible at all. The Education Department's new borrowing caps, set to take effect this year, would cut off that financing before it reaches them.
Twenty-five states and Washington, D.C., filed suit in U.S. District Court in Maryland on Tuesday to block the limits, according to The Hill. The Democratic attorneys general behind the lawsuit argue the caps will strain the healthcare workforce by discouraging students from entering medicine — particularly students who cannot absorb six-figure tuition gaps through family wealth or private lending. That framing is accurate as far as it goes. But it understates what is actually at stake.
This is not primarily a story about student debt. It is a story about which communities will have doctors in ten years — and which federal policy just made that outcome worse.
The federal graduate loan program — specifically the Grad PLUS program, which allows students to borrow up to the full cost of attendance — has functioned as the primary mechanism by which students from non-wealthy backgrounds finance medical and other graduate professional education. Private loans charge higher interest rates and require credit history or cosigners that first-generation students often cannot provide. Cutting Grad PLUS borrowing limits does not make medical school cheaper. It makes medical school inaccessible for students who cannot pay the gap another way.
The Education Department has framed the limits as a response to runaway graduate debt and institutional cost inflation — an argument that has surface plausibility. Graduate professional programs have raised tuition aggressively in part because federal lending made it possible. That is a real problem. But the proposed remedy targets the borrower, not the institution. It does nothing to cap what medical schools charge. It simply removes the financing that lets lower-income students attend them. The people who designed this policy know the difference. The choice to address cost inflation by restricting student access rather than institutional pricing is a policy decision with a clear distributional outcome: it protects the existing wealth-based structure of medical education.
The healthcare workforce consequences are not speculative. The Association of American Medical Colleges has documented a projected physician shortage of up to 86,000 doctors by 2036, with the deficit concentrated in primary care and in rural and underserved areas. The doctors most likely to fill those gaps are not graduates of wealthy families who attended elite private medical schools debt-free. They are graduates from underrepresented communities, first-generation college students, and students from the same rural and low-income backgrounds as the patients they are most likely to serve. Research consistently finds that physicians from underrepresented backgrounds are more likely to practice in underserved areas. Federal loan access is one of the primary mechanisms that makes their enrollment possible. Restricting it does not happen in a vacuum.
Physicians from low-income and underrepresented backgrounds are disproportionately likely to practice in rural, tribal, and low-income urban communities after graduation. Federal programs — including loan access, the National Health Service Corps, and rural residency incentives — exist precisely because market forces alone do not direct physicians toward the communities with the greatest need. Restricting graduate borrowing limits removes a foundational piece of that pipeline.
The attorneys general suing the department are making a procedural and substantive argument: that the Education Department exceeded its authority under the Higher Education Act, and that the policy will cause concrete harm to state healthcare systems. That argument is likely to find receptive courts — federal judges have been skeptical of sweeping executive rulemaking in education policy since the Supreme Court's 2022 ruling in West Virginia v. EPA established that major policy changes require clear congressional authorization. The states are essentially arguing that Congress never authorized the department to restructure graduate lending in a way that functionally eliminates access for large categories of students.
But the legal fight, however it resolves, should not obscure the underlying policy logic. The people who will be most affected by these caps are not the abstract "graduate borrowers" of policy debate. They are prospective physicians, nurses, dentists, and mental health providers who are currently deciding whether to apply to professional programs — and who will make that decision based in part on whether they can finance it. Many of them will decide they cannot. Some of those decisions are already being made.
The federal government's simultaneous investigation of medical school diversity programs aimed at reducing healthcare disparities compounds the picture. The administration is, at the same moment, restricting the financing mechanisms that enable low-income students to attend medical school and scrutinizing the programs designed to recruit them once they arrive. These are not unrelated policies. Together they constitute a coherent — if unstated — approach to who gets to become a doctor and who does not.
The communities absorbing that outcome are not in a position to absorb it. Rural counties already face primary care physician shortages that leave residents driving hours for basic care. Tribal health systems operate chronically understaffed. Low-income urban neighborhoods rely on federally qualified health centers that cannot fill their own provider vacancies. The global pattern of healthcare workforce collapse when public financing is withdrawn is not a hypothetical — it is documented, predictable, and in this case, preventable.
It is worth being precise about what the lawsuit can and cannot accomplish. If the states prevail, the caps are blocked and the status quo is preserved. That is a meaningful outcome. But the status quo is itself a system in which medical education costs have risen to levels that already exclude large numbers of qualified candidates. Winning the lawsuit does not fix that problem. It only prevents the administration from making it worse by fiat. The deeper question — why does it cost $330,000 to become a doctor, and who decided that was acceptable — is not before any court.
The states filing this suit are not wrong. The caps are bad policy, likely unlawful, and will cause measurable harm to healthcare access in communities that are already underserved. The lawsuit should succeed. But the administration's calculation — that restricting graduate lending is a defensible response to cost inflation — will outlast this particular legal challenge unless Congress acts to address what it actually controls: the pricing power of institutions that have spent decades treating federal loan access as a blank check. The borrowers caught between those two failures are not abstractions. They are the doctors America will not have.
